Article thumbnail

Characteristics of Suppressor Macrophages Induced by Mycobacterial and Protozoal Infections in relation to Alternatively Activated M2 Macrophages

By Haruaki Tomioka, Yutaka Tatano, Win Win Maw, Chiaki Sano, Yuichi Kanehiro and Toshiaki Shimizu


In the advanced stages of mycobacterial infections, host immune systems tend to change from a Th1-type to Th2-type immune response, resulting in the abrogation of Th1 cell- and macrophage-mediated antimicrobial host protective immunity. Notably, this type of immune conversion is occasionally associated with the generation of certain types of suppressor macrophage populations. During the course of Mycobacterium tuberculosis (MTB) and Mycobacterium avium-intracellulare complex (MAC) infections, the generation of macrophages which possess strong suppressor activity against host T- and B-cell functions is frequently encountered. This paper describes the immunological properties of M1- and M2-type macrophages generated in tumor-bearing animals and those generated in hosts with certain microbial infections. In addition, this paper highlights the immunological and molecular biological characteristics of suppressor macrophages generated in hosts with mycobacterial infections, especially MAC infection

Topics: Review Article
Publisher: Hindawi Publishing Corporation
OAI identifier:
Provided by: PubMed Central

Suggested articles


  1. A l i y ua n dH .M .S a l i h u ,“ T u b e r c u l o s i sa n dH I V disease: two decades of a dual epidemic,”
  2. (2001). A schistosome-expressed immunomodulatory glycoconjugate expands peritoneal Gr1+ macrophages that suppress naive CD4+ T cell proliferation via an IFN-γ and nitric oxide-dependent mechanism,”
  3. activation is a key event for the maintenance of a mycobacterial antigen-elicited pulmonary granulomatous response,”
  4. (2003). Alternative activation of macrophages,”
  5. (2008). An antiinflammatory role for IKKβ through the inhibition of “classical” macrophage activation,” J o u r n a lo fE x p e r i m e n t a lM e d -icine,
  6. and IL-10 as effectors that enable alternatively activated macrophages to inhibit the generation of classically activated macrophages,”
  7. (2005). Anti-inflammatory effects of macrolides— an underappreciated benefit in the treatment of communityacquired respiratory tract infections and chronic inflammatory pulmonary conditions?”
  8. (1996). APC from mice harbouring the filarial nematode, Brugia malayi,p r e -vent cellular proliferation but not cytokine production,”
  9. Assoian et al., “Transforming growth factor type β: rapid induction of fibrosis and angiogenesisinvivoandstimulationofcollagenformationin vitro,”
  10. (1997). ATP-induced killing of mycobacteria by human macrophages is mediated by purinergic P2Z(P2X7)r e c e p t o r s , ”Immunity,v o l .7 ,n o .3 ,p p .
  11. (2000). ATP-induced killing of virulent Mycobacterium tuberculosis within human macrophages requires phospholipase
  12. (2009). Autocrine IL-10 induces hallmarks of alternative activation in macrophages andsuppressesantituberculosiseffectormechanismswithout compromising T cell immunity,”
  13. (1978). BCG-induced suppressor cells. I. Demonstration of a macrophage-like suppressor cell that inhibits cytotoxic T cell generation in vitro,”
  14. (2006). Biochemical and functional characterization of three activated macrophage populations,”
  15. (2000). C.Ramstad,V.Sundvold,H.K.Johansen,andT.Lea,“cAMPdependent protein kinase (PKA) inhibits T cell activation by phosphorylating
  16. (1995). Cellular target of in vitro-induced suppressor cells derived from the spleen of Mycobacterium lepraemurium-infected mice and role of IFNγ in their development,”
  17. (1990). Characteristics of immunosuppressive macrophages induced in host spleen cells by Mycobacterium avium complex and Mycobacterium tuberculosis infections
  18. (1990). Characteristics of immunosuppressive macrophages induced in spleen cells by Mycobacterium avium complex infections in mice,”
  19. (1992). Characterization of immunosuppressive functions of murine peritoneal macrophages induced with various agents,”
  20. (1993). Characterization of suppressor function of human alveolar macrophages for T lymphocyte responses to phytohemagglutinin: cellular selectivity, reversibility, and early events in T cell activation,”
  21. (1997). Circulating profile of Th1 and Th2 cytokines in tuberculosis patients with different degrees of pulmonary involvement,”
  22. (2006). Comparative studies on the roles of mediator molecules in expression of the suppressor activity of Mycobacterium avium complex-induced immunosuppressive macrophages against
  23. (2004). Current Issues in Tuberculosis Control, Swiss Tropical Institute,
  24. (1992). Cyclophosphamide treatment antagonizes the in vitro development of Mycobacterium lepraemurium-induced suppressor cell precursors,”
  25. (1999). Cytokine production by rabbit alveolar macrophages: differences between activated and suppressor cell phenotypes,”
  26. (2011). Development of new antituberculous drugs based on bacterial virulence factors interfering with host cytokine networks,”
  27. (2010). Differential polarization of alveolar macrophages and bone marrowderived monocytes following chemically and pathogeninduced chronic lung inflammation,”
  28. (2002). Differential regulation of IL12 and IL-10 gene expression in macrophages by the basic leucine zipper transcription factor c-MAF fibrosarcoma,”
  29. (2009). Divergence of macrophage phagocytic and antimicrobial programs
  30. (2003). Dynamics of cytokine generation in patients with active pulmonary tuberculosis,”
  31. (1999). e d o t - P i r e n n e ,M .J .H e i l m a n ,M .S a x e n a
  32. (1995). Early redistribution of plasma membrane phosphatidylserineisageneralfeatureofapoptosisregardlessoftheinitiating stimulus: inhibition by overexpression of
  33. (2008). Exploring the full spectrum of macrophage activation,”
  34. (2003). F r i e d e n ,T .R .S t e r l i n g ,S .S .M u n s i ff,C .J .W a t t ,a n dC .
  35. (2011). Fibrosis is regulated by Th2 and Th17 responses and by dynamic interactions between fibroblasts and macrophages,”
  36. (1997). Further study on the roles of the effector molecules of immunosuppressive macrophages induced by mycobacterial infection in expression of their suppressor function against mitogenstimulated T cell proliferation,” Clinical and Experimental Immunology,
  37. (2007). G o l d m a n ,K .V .P l u m l e y ,a n dB .E .L a u g h o n ,“ T h e evolution of extensively drug resistant tuberculosis (XDRTB): history, status and issues for global control,”
  38. (2010). Galectin-9 expands immunosuppressivemacrophagestoameliorateT-cell-mediated lung inflammation,”
  39. (2007). Garc´ ıa-Bodel´ on et al., “Immune suppression in advanced chronic fascioliasis: an experimental study in a rat model,”
  40. (2008). Gene expression profiles of bronchoalveolar cells in pulmonary
  41. (2000). H i n g l e y - W i l s o n
  42. (1997). HAX-1, a novel intracellular protein, localized on mitochondria, directly associates with HS1, a substrate of Src family tyrosine kinases,”
  43. (2004). Human IL-23-producing type 1 macrophages promote but IL-10-producing type 2 macrophages subvert immunity to (myco) bacteria,”
  44. (2012). Human MSC suppression correlates with cytokine induction
  45. (2008). IL-10: the master regulator of immunity to infection,”
  46. (2008). IL-23 promotes maintenance but not commitment to the Th17 lineage,”
  47. (2008). IL-9 is associated with an impaired Th1 immune response in patients with tuberculosis,”
  48. (1992). Immunosuppressive activity induced by nitric oxide in culture supernatant of activated rat alveolar macrophages,”
  49. (2000). Incentives and disincentives for new anti-tuberculous drug development.
  50. (1996). Inhibition of T lymphocyte activation by cAMP is associated with downregulation of two parallel mitogen-activated protein kinase pathways,theextracellularsignal-relatedkinaseandc-JunNterminal kinase,”
  51. (2002). Innate immunity to Mycobacterium tuberculosis,”
  52. (1992). Interleukin 4 potently enhances murine macrophage mannose receptor activity: a marker of alternative immunologic macrophage activation,”
  53. (2011). Kr¨ uppel-like factor 4 regulates macrophage polarization,”
  54. (1991). M.A.SpiteriandL.W.Poulter,“Characterizationofimmune inducer and suppressor macrophages from the normal
  55. Macrophage activation by interferon: dissociation between tumoricidal capacity and suppressive activity,”
  56. Macrophage polarization and bacterial infections,” Current Opinion
  57. (2007). Macrophage polarization and insulin resistance: PPARγ in control,”
  58. (2008). Macrophage polarization in bacterial infections,”
  59. (2002). Macrophage polarization: tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes,”
  60. (2011). Macrophage polirazation: convergence point targeted by
  61. (2003). Macrophages in chronic type 2 inflammation have a novel phenotype characterized by the abundant expression of
  62. (2010). Macrophages, innate immunity and cancer: balance, tolerance, and diversity,”
  63. (2005). markers for murine, but not human, alternatively activated myeloid cells,”
  64. mediates immunosuppression following primary infection with toxoplasma gondii
  65. (2010). Mycobacterium tuberculosis activates human macrophage peroxisome proliferatoractivated receptor γ linking mannose receptor recognition to regulation of immune responses,”
  66. (1998). New tuberculosis drug development: how can we do better?”
  67. (1996). Nitric oxide-mediated suppression of T cell responses during Trypanosoma brucei infection: soluble trypanosome products and interferon-γ are synergistic inducers of nitric oxide synthase,”
  68. (2011). Obstacles and opportunities for understanding macrophage polarization,”
  69. P o t i a n ,W .R a fi ,K .B h a t t ,A .M c B r i d e ,W .C .G a u s e
  70. Phenotypic characterization of two cell populations involved in the acquisition of suppressor activity by cultured spleen cells from Mycobacterium lepraemurium-infected mice,” Clinical and ExperimentalImmunology,vol.102,no.3,pp.515–522,1995.
  71. (1996). Phospholipids and reactive nitrogen intermediates collaborate in expression of the T cell mitogenesis-inhibitory activity of immunosuppressive macrophages induced
  72. (2007). PPARs in alveolar macrophage biology,”
  73. (2002). Profiles of cell-to-cell interaction ofMycobacteriumintracellulare-inducedimmunosuppressive macrophages with target T cells in terms of suppressor signal transmission,”
  74. (1998). Profound suppression of cellular proliferation mediated by the secretions of nematodes,”
  75. (2010). Proinflammatory clearance of apoptotic neutrophils induces an IL12lowIL-10high regulatory phenotype in macrophages,”
  76. (2011). Protective and pathogenic functions of macrophage subsets,”
  77. R.Novak,S.Dabelic,andJ.Dumic,“Galectin-1andgalectin3 expression profiles in classically and alternatively activated human macrophages,”
  78. (2011). Regulators of macrophage activation,”
  79. (1991). Requirement for cellto-cell contact for the immunosuppressive activity of human alveolar macrophages,”
  80. (1998). Requirement for in vivo production of IL-4, but not IL-10, in the induction of proliferative suppression by filarial parasites,”
  81. (2001). Reversing lipopolysaccharide toxicity by ligating the macrophage Fcγ receptors,”
  82. (1997). Selective inhibition of T cell proliferation but not expression of effector function by human alveolar macrophages,”
  83. (2002). Stereotyped and specific gene expression programs in human innate immune responses to bacteria,”
  84. (2007). Structural basis for the inhibition of tyrosine kinase activity of ZAP-70,”
  85. (1998). Suppression of lymphoproliferation by alveolar macrophages in the guinea pig,”
  86. (1993). Suppression of murine IgM, IgG, IgA and IgE antibody responses by alveolar macrophages,”
  87. (1978). Suppressor adherent cells in human tuberculosis,”
  88. (1993). Suppressor macrophages in African trypanosomiasis inhibit T cell proliferative responses by nitric oxide and prostaglandins,”
  89. (2009). T cells in mycobacterial infection and disease,”CurrentOpinioninImmunology,vol.21,no.4,pp.378– 384,
  90. (2004). The chemokine system in diverse forms of macrophage activation andpolarization,”Trends in Immunology,
  91. (2012). The genus Broussonetia: a review of its phytochemistry and pharmacology,”
  92. (2004). The immunological aspects of latency in tuberculosis,”
  93. (1986). The immunology of mycobacterial diseases,”
  94. The role of B7 molecules in the cell contact-mediated suppression of T cell mitogenesis by immunosuppressive macrophages induced with mycobacterial infection,”
  95. (2008). The role of cytokines in the initiation, expansion, and control of cellular immunity to tuberculosis,”
  96. (1991). The role of the macrophage in induction of immunosuppression in Trypanosoma congolense-infected cattle,”
  97. (1995). The role of tumor necrosis factor, interferon-γ, transforming growth factor-β, and nitric oxide in the expression of immunosuppressive functions of splenic macrophages induced by Mycobacterium avium complex infection,”
  98. (1996). The role of tumour necrosis factor-α in combination with interferonγ or interleukin-1 in the induction of immunosuppressive macrophages because of Mycobacterium avium complex infection,”
  99. (2010). The TCR-mediated signaling pathways that control the direction of helper T cell differentiation,”
  100. (2006). Transcriptional profiling of the human monocyte-to-macrophage differentiation and polarization: new molecules and patterns of gene expression,”
  101. (2006). Transforming growth factor-β regulation of immune responses,”
  102. (1999). Treatment and implications of multidrugresistant tuberculosis for the 21st century,”
  103. (2004). tuberculosis persistence, latency, and drug tolerance,”
  104. (2001). Type 1/type 2 immunity in infectious diseases,”
  105. (2010). Y.Tatano,T.Shimizu,andH.Tomioka,“Propertiesofimmunosuppressive macrophages generated by Mycobacterium intracellulare infection in M. intracellulare-susceptible and resistant mice,”

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.